All In Biotech

Free tool

FAERS Monitor: Brineura

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761052 or its brand name (Brineura, Cerliponase Alfa). Reports on generic versions are filed under their own applications.

Reports

536

Serious

391

73% of reports

Hospitalization

196

Death reported

26

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pyrexia91
  • seizure79
  • vomiting38
  • device related infection31
  • device leakage28
  • csf culture positive26
  • pneumonia26
  • headache22
  • drug ineffective20
  • off label use18
  • device occlusion16
  • general physical health deterioration16
  • nausea16
  • dystonia15
  • disease progression14

Reports by year received

View as table
YearReports
20179
201829
201946
202052
202183
202284
202373
202452
202571
202637

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,623 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
csf culture positiveSignal2612765.78268.7240,918
device related infectionSignal3179.256.32,314
device occlusionSignal1644.727.6640
dystoniaSignal1530.418.4397
seizureSignal7926.921.91,950
device leakageSignal2825.417.7632
pyrexiaSignal9110.38.6769
general physical health deteriorationSignal165.43.354
disease progressionSignal144.62.837
vomitingSignal383.22.356
pneumoniaSignal263.22.237
headache221.40.92
off label use180.80.51
nausea160.80.51
drug ineffective200.60.45

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.